Oramed Pharmaceuticals (ORMP) Return on Invested Capital (2017 - 2024)

Oramed Pharmaceuticals (ORMP) posted Return on Invested Capital of 0.0% for Q4 2024, down 288.47% on a QoQ basis from 0.0% in Q3 2024.

Oramed Pharmaceuticals (ORMP) Return on Invested Capital (2017 - 2024) Analysis & Trends

Oramed Pharmaceuticals' Return on Invested Capital history runs 3 years deep, the most recent figure standing at 0.0% for Q4 2024.

Quarterly Return on Invested Capital changed N/A year-over-year to 0.0% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 0.0% (changed N/A YoY) and the FY2019 annual result came in at 2.72%, changed N/A from the prior year.
Return on Invested Capital was 0.0% for Q4 2024 at Oramed Pharmaceuticals, down from 0.0% in the prior quarter.
Across five years, Return on Invested Capital topped out at 0.0% in Q3 2024 and bottomed at 0.0% in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROIC (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	0.00%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	0.04%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Oramed Pharmaceuticals	170.25 Mn	170.25 Mn	-	-

Download Data